Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Gentuzumab-Ozogamicin, Citosine Arabinoside, G-CSF Combination (G-AraMy) in the Treatment of Secondary Acute Myeloid Leukemia in Elderly Patients.

Livio Pagano, MD, Luana Fianchi, MD, Franco Leoni, MD, Sergio Storti, MD, Maria Teresa Voso, MD, Caterina Giovanna Valentini, MD, Alessandra Scardocci, MD, Morena Caira, MD, Alberto Bosi, MD, Giupeppe Leone, MD

Blood (2007) 110 (11): 4377.

https://doi.org/10.1182/blood.V110.11.4377.4377

Published: 2007

Journal Articles

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Barbara Peruta, BSc, Vittoria Guerini, BSc, Giuseppe Rossi, MD, Enrico Pogliani, MD, Eros Di Bona, MD, Pietro Fabris, MD, Agostino Cortelezzi, MD, Teodoro Chisesi, MD, Emanuele Angelucci, MD, Franco Leoni, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 3497.

https://doi.org/10.1182/blood.V110.11.3497.3497

Published: 2007

Journal Articles

Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus Thalidomide in Refractory Myeloma.

Stefania Ciolli, MD, Franco Leoni, md, Cinzia Casini, md, Carla Breschi, md, Alberto Bosi, phd

Blood (2006) 108 (11): 5087.

https://doi.org/10.1182/blood.V108.11.5087.5087

Published: 2006

Journal Articles

Gentuzumab-Ozogamicin,Citosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.

Luana Fianchi, MD, Franco Leoni, MD, Sergio Storti, MD, Sergio Rutella, MD, Giacomo Gianfaldoni, MD, Maria Teresa Voso, MD, Stefano Bosi, MD, Livio Pagano, MD, Giuseppe Leone, MD

Blood (2005) 106 (11): 4604.

https://doi.org/10.1182/blood.V106.11.4604.4604

Published: 2005

Journal Articles

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Giuseppe Rossi, MD, Enrico M. Pogliani, MD, Emanuele Angelucci, MD, Pietro Fabris, MD, Giorgio Lambertenghi-Deliliers, MD, Paola Polistena, MD, Eros Di Bona, MD, Fabio Ciceri, MD, Franco Leoni, MD, Claudia Minotto, MD, Daniele Mattei, MD, Maurizio Musso, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2005) 106 (11): 1836.

https://doi.org/10.1182/blood.V106.11.1836.1836

Published: 2005

Journal Articles

Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).

Massimo Offidani, MD, Laura Corvatta, MD, Lara Malerba, MD, Monica Marconi, MD, Massimo Catarini, MD, Riccardo Centurioni, MD, Franco Leoni, MD, Anna Rita Scortechini, MD, Maria Cristiana Masia, MD, Pietro Leoni, MD

Blood (2004) 104 (11): 4490.

https://doi.org/10.1182/blood.V104.11.4490.4490

Published: 2004

NARROW

Gentuzumab-Ozogamicin, Citosine Arabinoside, G-CSF Combination (G-AraMy) in the Treatment of Secondary Acute Myeloid Leukemia in Elderly Patients.

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus Thalidomide in Refractory Myeloma.

Gentuzumab-Ozogamicin,Citosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Gentuzumab-Ozogamicin, Citosine Arabinoside, G-CSF Combination (G-AraMy) in the Treatment of Secondary Acute Myeloid Leukemia in Elderly Patients.

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus Thalidomide in Refractory Myeloma.

Gentuzumab-Ozogamicin,Citosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only